Express Scripts adds Vivus' Qsymia to its standard benefits program
US drugmaker Vivus (Nasdaq: VVUS) says that Express Scripts, among the USA’s largest Pharmacy Benefit Managers (PBMs), has added the firm’s weight loss product Qsymia (phentermine and topiramate extended-release) to its national pharmacy formularies, allowing for coverage where available by benefit design of the first new Food and Drug Administration-approved medication commercially available in the USA in over a decade for the treatment of chronic weight management.
Back in the fall, Vivus announced that Express Scripts has joined the Qsymia Certified Home Delivery Pharmacy Network. At the time, Qsymia was only available through mail order from the Qsymia Certified Home Delivery Pharmacy Network as a part of the Qsymia Risk Evaluation and Mitigation Strategy program (The Pharma Letter October 10)
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze